Figures computed from official regulatory filings — .
Analysttarget 60 USD (+2813%)
Ownershipinsiders 8.31% · institutions 6.52% · short 0.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cardio Diagnostics Holdings, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
11 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Intrater James | AwardD (derivative) | $6.2K | SEC |
| Fung Peter K | AwardD (derivative) | $6.2K | Unusual size | SEC |
| Betts Wendy J | AwardD (derivative) | $6.2K | Unusual size | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.2K | SEC |
| Betts Wendy J | AwardD (derivative) | $6.3K | SEC |
| Intrater James | AwardD (derivative) | $6.3K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.3K | SEC |
| Fung Peter K | AwardD (derivative) | $6.3K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.2K | SEC |
| Intrater James | AwardD (derivative) | $6.2K | SEC |
| Fung Peter K | AwardD (derivative) | $6.2K | SEC |
| Betts Wendy J | AwardD (derivative) | $6.2K | SEC |
| Intrater James | AwardD (derivative) | $6.2K | SEC |
| Betts Wendy J | AwardD (derivative) | $6.2K | SEC |
| Fung Peter K | AwardD (derivative) | $6.2K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.2K | SEC |
| Intrater James | AwardD (derivative) | $6.3K | SEC |
| Fung Peter K | AwardD (derivative) | $6.3K | SEC |
| Betts Wendy J | AwardD (derivative) | $6.3K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.3K | SEC |
| Betts Wendy J | AwardD (derivative) | $6.2K | SEC |
| Fung Peter K | AwardD (derivative) | $6.2K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.2K | SEC |
| Intrater James | AwardD (derivative) | $6.2K | SEC |
| Burton Paul Frederick | AwardD (derivative) | $6.2K | SEC |